In malignant glioma and prostate cancer, avasimibe-mediated SOAT1 inhibition could elevate intracellular cholesterol content, consequently impeding SREBP1 activity and SREBP1-modulated fatty acids synthesis and uptake10,12. This evidence concerns the gene SOAT1 and prostate carcinoma.